Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million$325 million from its previously issued $320 million$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If...
Business Wire
More News
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PR Newswire NEW YORK, July 31, 2026 Phathom...
PR Newswire
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?
Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.
Stocktwits
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) PR Newswire...
PR Newswire
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 7.5% - Should You Buy...
MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS
Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by...
MarketBeat
Phathom Pharmaceuticals Q1 Earnings Call Highlights
Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized...
MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings Miss
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 16.2% on Disappointing Earnings...
MarketBeat
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga

Advertisement|Remove ads.